About GlyCardial Diagnostics

GlyCardial Diagnostics is a spin-off company of the Catalan Institute of Cardiovascular Sciences (ICCC) and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia. The technology is based on the detection of Apo J-Glyc in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution after an ischemic event.

Company Highlights
Year Founded

2017

icon-altEmployees

2

Location (HQ)

ESP

Since Last Funding

5 years 8 months

Monthly Website Visitors

440

icon-altTotal Investment Amt

$5.1M

Last Funding Round

Grant

icon-altYoY Headcount Growth

-58.82%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Health Care

Pharmaceutical

Life Science

Biotechnology

Biotechnology Research

Medical Device

Health Diagnostics